| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Lifeward Ltd.$7.2
+0.27 (+3.9%)
Market Cap
19.84 M
EPS
-19.68
P/E Ratio
-
Value Trade
102.66 K
SEC Financials
Q1 2026Dilution Risk
Revenue
3.92 M
R&D Expenses
5.84 M
Operating CF
-3.67 M
Total Assets
33.42 M
Total Liabilities
27.13 M
Equity
6.29 M
D/E Ratio
12,345
5.38 %
Week
-6.25 %
1 Month
30.56 %
3 Month
15.2 %
6 Month
-95.39 %
5 Year
-99.97 %
All Time
Cash Data
Cash Position
11.42 M
Monthly Burn
1.23 M
Runway
8.1 mo
Burn Trend
StableSEC Filing
May 20, 2026
Overview
Volume
4.70 K
52 Week Range
4.14 - 15.24
% held by Insiders
46.81 %
% held by Institutions
0.5 %
Enterprise Value
17.22 M
Total Shares
2.81 M
Short %
3.86 %
Float Shares
2.75 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LFWD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
LFWD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LFWD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LFWD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LFWD Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
LFWD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LFWDLifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
Lifeward has appointed Dr. Keith D. Rose as Chief Medical Officer to enhance its neurorehabilitation portfolio and biomedical platform. Dr. Rose, with over 30 years of experience in rehabilitation medicine and neuroscience, will lead the company's global medical strategy. His prior roles have significantly contributed to Lifeward's medical affairs and strategic initiatives.
Read more →LFWDLifeward Reports First Quarter 2026 Financial Results
Lifeward Ltd. reported its financial results for Q1 2026, highlighting a successful strategic transaction with Oratech that brought $10 million in financing. The company noted a decrease in total revenue by 22% year-over-year, alongside a significant rise in operating expenses due to one-time charges related to the acquisition. Despite these financial challenges, Lifeward has managed to decrease its operating cash burn and has improved its operational efficiencies as it prepares for upcoming product trials and growth in neurorehabilitation technologies.
Read more →LFWDLifeward to Report First Quarter 2026 Financial Results on May 15, 2026
Lifeward Ltd. will announce its first quarter 2026 financial results on May 15, 2026. Following the announcement, CEO Mark Grant and CFO Almog Adar will host a conference call to discuss the results. Lifeward is known for its advanced neurorehabilitation technologies and is expanding into new therapeutic platforms, including oral delivery of biologic drugs.
Read more →LFWDLifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton
Lifeward presented new data on the ReWalk powered exoskeleton at the ASIA 2026 conference, highlighting a significant decline in lower extremity fractures among users. The study showed a fracture prevalence of just 3% since 2013, with zero fractures reported in Germany since 2018. These findings reinforce the safety profile of ReWalk and support its adoption for spinal cord injury mobility.
Read more →LFWDLifeward Successfully Closes on Strategic Partnership with Oramed
Lifeward Ltd. has finalized its strategic partnership with Oramed Pharmaceuticals, enhancing its position in the biomedical innovation sector. The partnership includes access to $47 million in capital, with an immediate $10 million drawdown. This collaboration is expected to pave the way for profitability and expand Lifeward's technological capabilities.
Read more →LFWDLifeward Reports Fourth Quarter and Full Year 2025 Financial Results
Lifeward Ltd. reported its fourth quarter and full year financial results for 2025, showcasing a strategic transition towards a diversified biomedical innovation company. The company received shareholder approval for a transformative deal with Oramed to acquire its POD™ technology, while also announcing the acquisition of powered upper-body exoskeleton technology. Despite a revenue decline of 33% in Q4 2025, Lifeward improved operational efficiency and expanded reimbursement coverage for its existing products, positioning itself for positive cash flow in 2026.
Read more →LFWDLifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
Lifeward has received shareholder approval to finalize a strategic partnership with Oramed Pharmaceuticals, which will enhance its position as a diversified biomedical company. This partnership allows Lifeward to integrate Oramed's POD™ oral delivery technology, potentially transforming treatment approaches for chronic diseases. The agreement also provides Lifeward access to approximately $47 million in capital to support its growth and profitability goals.
Read more →LFWDLifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement
Lifeward Ltd. has announced that it has regained compliance with Nasdaq's minimum bid price requirement, confirming that its stock maintained a minimum closing bid price of $1.00 for at least 10 consecutive business days. The Nasdaq Listing Qualifications Staff has now closed the matter regarding the prior bid price deficiency. Lifeward is recognized for its innovative medical technologies aimed at transforming the lives of those with physical limitations or disabilities, allowing it to continue trading on the Nasdaq Capital Market.
Read more →LFWDLifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
Lifeward Ltd. announced that it will report its fourth quarter and full year 2025 financial results on March 18, 2026. Company executives will host a conference call to discuss these results, which can be accessed by analysts and investors via multiple channels. Lifeward is recognized for its innovative medical technologies that aim to improve the lives of individuals with physical limitations. The company’s commitment to innovation is highlighted through their range of products designed for rehabilitation.
Read more →LFWDLifeward Announces Collaboration With Shirley Ryan AbilityLab to Expand Access for the ReWalk Personal Exoskeleton
Lifeward Ltd. has partnered with Shirley Ryan AbilityLab to launch specialized clinics aimed at enhancing access to the ReWalk Personal Exoskeleton for individuals with spinal cord injuries. This collaboration, starting in the second quarter of 2026, will streamline the evaluation process and provide training and support for patients. The initiative is expected to promote greater independence and improved health outcomes for users.
Read more →LFWDLifeward to Acquire Powered Upper Body Exoskeleton with AI Capabilities Designed to Restore Function to Stroke Survivors
Lifeward Ltd. has announced its acquisition of technology assets from Skelable Ltd., including a powered upper body exoskeleton designed to assist stroke survivors. The acquisition, valued at $480,000, aims to expand Lifeward's portfolio and enhance its position in the neuro-rehabilitation market. The device is expected to launch commercially within 18 to 24 months, supporting patients in regaining functional movement.
Read more →LFWDLifeward Announces Reverse Share Split
Lifeward Ltd. announced a 1-for-12 reverse share split effective February 24, 2026, following shareholder approval. This move aims to increase the per share price to meet Nasdaq listing standards. The company will also raise its authorized share capital to 100 million shares. The reverse split will adjust outstanding warrants and stock options proportionately.
Read more →LFWDLifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers
Lifeward's ReWalk Personal Exoskeleton is now covered by Aetna, joining Humana and UnitedHealthcare in providing Medicare Advantage coverage. This expansion allows approximately 16 million beneficiaries access to the device, which is recognized as medically necessary for individuals with spinal cord injuries. The decision is seen as a significant step in enhancing rehabilitation technology access.
Read more →LFWDLifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
Lifeward has entered a strategic partnership with Oramed Pharmaceuticals, which includes a $47 million investment aimed at enhancing Lifeward's financial position and diversifying its portfolio. The partnership allows Lifeward to integrate Oramed's Protein Oral Delivery (POD™) technology, targeting the injectable drugs market, particularly for diabetes treatments. This collaboration is expected to position Lifeward for profitability while exploring significant growth opportunities.
Read more →LFWDLifeward Appoints Bob Marshall as Chairman of the Board
Lifeward Ltd. has appointed Bob Marshall as the new Chairman of the Board, effective January 1, 2026, succeeding Joseph Turk. Marshall, who has been a board member since 2024, brings valuable financial and healthcare expertise to the role. Turk is moving on to a CEO position at Fresenius Medical Care, marking a significant leadership transition for Lifeward.
Read more →LFWDLifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates
Lifeward has announced a new distribution agreement with Verita Neuro to expand access to its ReWalk Personal Exoskeleton in Mexico, Thailand, and the UAE. This partnership aims to enhance clinical adoption through a new in-patient training model, addressing the needs of spinal cord injury patients. The initiative is part of Lifeward's strategy to grow its international presence and support rehabilitation efforts.
Read more →LFWDLifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval
Lifeward Ltd. has received prior authorization from Humana Medicare Advantage Plan for its ReWalk 7 Personal Exoskeleton, following a similar approval from UnitedHealthcare. This development is expected to enhance access for individuals with spinal cord injuries and strengthen Lifeward's revenue dynamics. The approval reflects a growing trend in Medicare Advantage plans to support innovative medical technologies.
Read more →LFWDUnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton
Lifeward Ltd. has received its first prior authorization from UnitedHealthcare for the ReWalk 7 Personal Exoskeleton, marking a significant step in providing advanced assistive technology to individuals with spinal cord injuries. This approval reflects UnitedHealthcare's commitment to enhancing mobility and quality of life for its members. CEO Mark Grant highlighted the positive impact on reimbursement predictability and growth potential in the U.S. market.
Read more →LFWDLifeward Ltd. Reports Third Quarter 2025 Financial Results
Lifeward Ltd. reported its third quarter 2025 financial results, highlighting a record number of ReWalk systems placed for Medicare beneficiaries. The company achieved a 16% reduction in cash burn and a 27% decrease in Non-GAAP operating loss. Despite a slight increase in net loss, Lifeward's revenue grew by 1% year-over-year, driven by Medicare-related sales. The company also secured a $3.0 million loan agreement to bolster its liquidity.
Read more →LFWDLifeward to Report Third Quarter Financial Results on November 14, 2025
Lifeward Ltd. will release its third quarter financial results on November 14, 2025, before market opening. CEO Mark Grant and CFO Almog Adar will discuss the results during a conference call at 8:30 a.m. EST. The event will be accessible via a live webcast on the company's website.
Read more →LFWDFirst Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton
Lifeward Ltd. announced it has received its first payment from a commercial Medicare Advantage Plan for the ReWalk 7 Personal Exoskeleton. The company is experiencing faster claim approvals, with most being processed within 30-60 days. This development follows a finalized Medicare reimbursement pathway for personal exoskeletons by CMS, enhancing access for individuals with spinal cord injuries.
Read more →LFWDLifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton
Lifeward Ltd. has received CE mark approval for its ReWalk 7 Personal Exoskeleton, allowing it to be sold commercially in Europe. This advanced exoskeleton features cloud connectivity and customizable walking speeds, enhancing mobility for individuals with spinal cord injuries. The approval is expected to drive revenue growth, particularly in Germany, where reimbursement processes are well-established.
Read more →LFWDLifeward Ltd. Reports Second Quarter 2025 Financial Results
Lifeward Ltd. reported its financial results for Q2 2025, showing a revenue decrease of 15% year-over-year, totaling $5.7 million. Despite the decline, the company noted a record number of ReWalk systems placed for Medicare beneficiaries and a growing pipeline. New leadership aims to enhance strategic direction and operational efficiency. The company anticipates a revenue target of $24–$26 million for the full year.
Read more →LFWDLifeward Names Almog Adar as New CFO, Strengthening Executive Leadership
Lifeward Ltd. has appointed Almog Adar as its new Chief Financial Officer, succeeding his role as Vice President of Finance. Adar has been with the company since 2020, contributing significantly to its financial strategy. He expressed enthusiasm for his new role, emphasizing opportunities for growth and a commitment to strengthening the company's financial foundation.
Read more →LFWDLifeward to Report Second Quarter Financial Results on August 14, 2025
Lifeward Ltd. (Nasdaq: LFWD) will announce its second quarter financial results on August 14, 2025, prior to market opening. President Mark Grant and VP of Finance Almog Adar will discuss the results in a conference call at 8:30 a.m. EDT. Lifeward specializes in developing medical solutions for individuals with physical limitations, showcasing a commitment to innovation in the field. The company operates in the United States, Israel, and Germany, highlighting a broad international presence.
Read more →LFWDLifeward Expands Distribution Partnership with SportsMed Ltd. to Add Coverage for United Arab Emirates and Entire Gulf Cooperation Council Region
Lifeward Ltd. has expanded its distribution partnership with SportsMed Products Ltd. to include the United Arab Emirates and the Gulf Cooperation Council region. This move aims to enhance the reach of Lifeward's AlterG product lines. The partnership is expected to leverage SportsMed's strong market presence and expertise in the region, further driving growth.
Read more →LFWDLifeward Announces Closing of $2.6 Million Public Offering
Lifeward Ltd. has successfully closed a public offering, raising approximately $2.6 million by selling 4 million ordinary shares and accompanying warrants. The offering was facilitated by H.C. Wainwright & Co. The funds will be utilized for commercial efforts, working capital, and general corporate purposes. The company aims to enhance its innovative medical technology solutions.
Read more →LFWDLifeward Announces Pricing of $2.6 Million Public Offering
Lifeward Ltd. has announced a public offering of 4 million ordinary shares priced at $0.65 each, aiming to raise approximately $2.6 million. The offering includes warrants for the same number of shares, which are exercisable immediately. The proceeds will be used for commercial efforts and general corporate purposes. The closing is expected on June 26, 2025, pending customary conditions.
Read more →LFWDAdministrative Law Judge Determines ReWalk Personal Exoskeleton is “Reasonable and Necessary” for Medicare Beneficiary
Lifeward Ltd. announced that an Administrative Law Judge ruled in favor of a Medicare beneficiary's appeal for coverage of the ReWalk Personal Exoskeleton. This ruling classifies the device as 'reasonable and necessary' for individuals with spinal cord injuries, paving the way for expanded access and reimbursement. The decision builds on previous Medicare pathways established by CMS.
Read more →LFWDLifeward Names Mark Grant as New CEO
Lifeward Ltd. has appointed Mark Grant as its new CEO, effective June 2, 2025. Grant has a wealth of experience from his previous roles at Medtronic and IMRA Surgical, emphasizing his readiness to lead Lifeward into its next growth phase. The company recently achieved Medicare payment for its ReWalk exoskeleton, and Grant aims to leverage Lifeward's strengths in innovative medical technologies to foster sustainable growth and profitability.
Read more →LFWDLifeward to Present at Sidoti Virtual Investor Conference on May 21
Lifeward, a leader in medical technology, will present at the Sidoti Virtual Investor Conference on May 21-22, 2025. CEO Larry Jasinski and CFO Mike Lawless are scheduled to host a corporate presentation and one-on-one meetings with investors. The event aims to highlight Lifeward's commitment to innovation in the rehabilitation field and provide insights into their product portfolio. Registration for the conference is free and open to all interested investors.
Read more →LFWDLifeward Ltd. Reports First Quarter 2025 Financial Results
Lifeward Ltd. reported its financial results for the first quarter of 2025, highlighting the launch of the ReWalk 7 personal exoskeleton and significant revenue growth from AlterG products. Despite a slight decrease in total revenue compared to the previous year, the company achieved a reduction in operating loss and improved gross margins. Partnerships with CorLife and BARMER are expected to enhance market penetration and distribution capabilities. Overall, the outlook remains cautiously optimistic as Lifeward aims to expand its revenue through innovative product offerings and strategic collaborations.
Read more →LFWDLifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons
Lifeward Ltd. has completed a research program as part of the Israel Innovation Authority's MAGNET incentive program in collaboration with the Human Robot Interaction Consortium. The program aimed to develop technologies that integrate artificial intelligence with Lifeward's ReWalk Personal Exoskeleton, showcasing a successful proof-of-concept prototype. This initiative could lead to improved usability and adaptability of exoskeletons across various user environments. Lifeward's cooperation with top researchers reflects a commitment to advancing wearable robotics to transform the lives of individuals with physical limitations or disabilities.
Read more →LFWDLifeward to Report First Quarter 2025 Financial Results on May 15, 2025
Lifeward Ltd. has announced that it will release its first quarter 2025 financial results on May 15, 2025. The announcement includes details of a conference call where the CEO and CFO will discuss the results. Lifeward is recognized for its innovative products aimed at improving the lives of individuals with physical limitations and operates in multiple countries, including the U.S., Israel, and Germany.
Read more →LFWDLifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. Market
Lifeward has launched the ReWalk 7 Personal Exoskeleton in the U.S., enhancing mobility options for individuals with spinal cord injuries. This latest version features customizable walking speeds, cloud connectivity, and improved user control. The product has been developed with feedback from over two dozen end users and physical therapists, ensuring real-world applicability. The ReWalk 7 received FDA clearance in March 2025, and aims to provide a more effective walking solution for patients. Lifeward's innovations are part of a broader commitment to improving the lives of those with physical limitations.
Read more →LFWDLifeward Ltd. Reports Fourth Quarter and Full Year 2024 Financial Results
Lifeward Ltd. reported significant financial results for Q4 and the full year 2024, achieving record revenues of $7.5 million and $25.7 million respectively. The company experienced a substantial 130% increase in ReWalk exoskeleton sales due to Medicare coverage, while also launching its 2025 Sustainable Growth Plan aimed at profitability. Despite these successes, operating losses grew to $15.2 million, and there was a decline in ReWalk sales owing to delays in training sessions. Lifeward anticipates revenue growth in 2025 with a forecast of $28 million to $30 million.
Read more →LFWDLifeward and CorLife Finalize Partnership to Expand Workers’ Compensation Access to ReWalk Exoskeleton
Lifeward has partnered with CorLife to distribute the ReWalk Personal Exoskeleton for individuals with Workers’ Compensation claims. This collaboration is expected to enhance access to the exoskeleton, which enables paralyzed individuals to stand and walk. With CorLife managing the reimbursement process, Lifeward aims to increase awareness and extend its reach within the Workers’ Compensation market, benefiting injured workers significantly. Both companies express enthusiasm about improving the quality of life for those affected by spinal cord injuries through this partnership.
Read more →LFWDLifeward and MYOLYN Expand Partnership to Enhance Patient Access to MyoCycle FES Cycling Therapy System for Home Use
Lifeward Ltd. and MYOLYN, Inc. have expanded their partnership to enhance access to the MyoCycle FES Cycling Therapy System for home use. This agreement extends Lifeward's management of referrals and sales to patients transitioning from clinical to home-based therapy. MYOLYN will continue servicing patients already discharged from therapy. Both companies aim to improve patient care and rehabilitation outcomes through this collaboration.
Read more →LFWDLifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025
Lifeward Ltd. will release its fourth quarter and fiscal year-end financial results on March 7, 2025, prior to market opening. A conference call and webcast will be held at 8:30 a.m. EST for analysts and investors. Lifeward is focused on developing medical technology to assist those with physical limitations and disabilities, showcasing a commitment to innovation and care across its product range. Founded in 2001, the company operates globally, including in the U.S., Israel, and Germany.
Read more →LFWDLifeward Announces CEO Transition
Lifeward Ltd. has announced the retirement of CEO Larry Jasinski after 13 years of service, during which he significantly advanced the company’s mission to support individuals with physical limitations. The board has initiated a search for a new CEO, which may involve both internal and external candidates. As a result of this transition, the company has postponed its upcoming virtual investor event until later in 2025. Lifeward's preliminary financial results for fiscal year 2024 indicate expected revenue of approximately $25.7 million, aligning with prior guidance.
Read more →LFWDLifeward Finalizes Personal Exoskeleton Reimbursement Agreement with BARMER, Adding 8.5 Million Covered Lives in Germany
Lifeward Ltd. has finalized a reimbursement agreement with BARMER, the second-largest statutory health insurer in Germany, expanding coverage for ReWalk personal exoskeletons. This agreement will benefit approximately 8.5 million insured individuals, allowing those with spinal cord injuries easier access to these devices. The contract establishes a formal reimbursement process for eligible beneficiaries, marking an important step in the integration of advanced rehabilitation solutions in healthcare systems. Lifeward's CEO expressed optimism that this will lead to greater insurance coverage for exoskeleton technology both in Germany and internationally.
Read more →LFWDLifeward to Host Virtual Investor Event to Discuss Commercial Strategy, Key Initiatives, and Financial Outlook on February 20, 2025
Lifeward Ltd. announced it will host a virtual investor event on February 20, 2025, to discuss its commercial strategy, key initiatives, and financial outlook. The event will include presentations by executive leadership and highlight innovative products such as the ReWalk Exoskeleton and AlterG Anti-Gravity System. The webcast aims to inform investors, analysts, and interested parties about Lifeward’s mission to empower individuals with physical limitations through groundbreaking solutions.
Read more →LFWDLifeward CEO Issues Year-End 2024 Open Letter to Shareholders and Provides 2025 Commercial and Operational Priorities
Lifeward Ltd. (LFWD) issued an open letter from CEO Larry Jasinski, detailing the company's 2024 achievements and outlining 2025 strategies. Lifeward succeeded in establishing a defined Exoskeleton category and significantly increased delivery of ReWalk systems. The company aims to enhance its commercial focus and technology development in the coming year, with a particular emphasis on new product lines and expanding market presence. Lifeward also announced a successful capital raise to support its operational objectives and improve liquidity.
Read more →LFWDLifeward Cancels Its Extraordinary General Meeting of Shareholders
Lifeward Ltd. has announced the cancellation of its Extraordinary General Meeting of Shareholders originally scheduled for January 13, 2025. The Board of Directors has decided to withdraw the proposals set forth in the company's Definitive Proxy Statement, intending to present them at a future meeting in 2025. This decision reflects a strategic shift for the company as it continues to focus on its innovative portfolio in physical rehabilitation and recovery.
Read more →LFWDLifeward Announces Closing of $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Lifeward Ltd. has announced the closing of a $5 million registered direct offering priced at-the-market under Nasdaq rules. The offering involved the issuance of 1,818,183 ordinary shares at $2.75 each, alongside unregistered warrants for the same number of shares. The gross proceeds from the offering will be utilized for continued commercial efforts, working capital, and general corporate activities. The company operates in the rehabilitation sector and aims to deliver transformative health solutions.
Read more →LFWDLifeward Announces $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Lifeward Ltd. (Nasdaq: LFWD) has announced a registered direct offering aimed to raise approximately $5 million by selling 1,818,183 ordinary shares at $2.75 each. This offering, managed by H.C. Wainwright & Co., is expected to close on January 8, 2025, subject to customary conditions. Proceeds from this offering will go toward commercial efforts, working capital, and general corporate purposes. The company's strategic focus on developing innovative rehabilitation products continues to enhance its market leadership.
Read more →LFWDLifeward Announces Postponement of its Extraordinary General Meeting of Shareholders
Lifeward Ltd. has announced the postponement of its Extraordinary General Meeting of Shareholders, originally scheduled for December 30, 2024, now set for January 13, 2025, due to an expected lack of quorum. The unchanged record date remains November 20, 2024, and the company's Board of Directors recommends voting in favor of the proposals outlined in the proxy statement. Additionally, Lifeward is planning to host an Investor Day following the Meeting, which has not yet been dated.
Read more →LFWDLifeward Ltd. Reports Third Quarter 2024 Financial Results
Lifeward Ltd. reported strong financial results for Q3 2024, achieving a 39% revenue increase to $6.1 million, driven by sales from ReWalk systems and AlterG products. The company is integrating operations to enhance efficiency, expecting to save $3 million in operating expenses. Additionally, the successful launch of the AlterG NEO has spurred customer interest and positioned the product line for growth. Despite reporting an operating loss, management expresses optimism about future revenue growth as Medicare claims increase.
Read more →LFWDLifeward Announces Appointment of Robert J. Marshall to Its Board of Directors
Lifeward Ltd. has announced the appointment of Robert J. Marshall Jr. to its Board of Directors, effective November 2, 2024. Mr. Marshall brings a wealth of experience from his current role as CFO at Lantheus Holdings and previous positions in the medical device industry. He will serve as Chairman of the Audit Committee and is expected to provide valuable insights and strategic guidance. The appointment is seen as a proactive measure to further Lifeward's mission in advancing rehabilitation solutions for individuals with physical disabilities.
Read more →LFWDLifeward to Report Third Quarter Financial Results on November 12, 2024
Lifeward Ltd. (Nasdaq: LFWD) will announce its third quarter financial results on November 12, 2024, prior to the market opening. CEO Larry Jasinski and CFO Michael Lawless will discuss the results during a conference call and webcast at 8:30 a.m. EST. Lifeward is noted for its innovative solutions in rehabilitation and support for individuals with physical disabilities and limitations.
Read more →LFWDLifeward Streamlines U.S. Operations in Next Phase of Growth and Operational Efficiencies
Lifeward Ltd. announced plans to streamline its U.S. operations, including the closure of two facilities, which follows its recent acquisition of AlterG. This consolidation is expected to save the company around $3 million and improve its gross margins by approximately 200 basis points by 2025. The restructuring will also lead to a reduction of more than 35% in total headcount, as key functions are integrated into the Marlborough, Massachusetts facility. The CEO emphasizes that these changes will contribute to Lifeward's evolution towards better commercial execution and increased profitability.
Read more →LFWDLifeward Ltd. to Present at ThinkEquity Conference on Oct 30, 2024
Lifeward Ltd. has announced that its Chief Financial Officer, Mike Lawless, will present at the ThinkEquity Conference on October 30, 2024. The presentation aims to provide an overview of the company's innovative solutions in rehabilitation and recovery. Attendees can access the live presentation and will have the opportunity to engage in one-on-one meetings. Lifeward has a robust portfolio, including the ReWalk Exoskeleton and the AlterG Anti-Gravity system, designed to empower individuals with physical disabilities.
Read more →LFWDLifeward Launches Direct Sales of AlterG Product Line in Germany
Lifeward Ltd. has announced the direct sale of its AlterG product line in Germany, effective immediately. This decision was made public at the REHACARE 2024 conference in Düsseldorf, where the new AlterG NEO was showcased. The company anticipates increased revenue and profitability by focusing on a direct sales strategy, building on existing customer relationships in the German market. Lifeward aims to enhance its presence and efficiency in rehabilitation solutions through this venture.
Read more →LFWDLifeward Announces Appointment of Dr. Keith E. Tansey as Consulting Director of Clinical Research
Lifeward announced the appointment of Dr. Keith E. Tansey as the Consulting Director of Clinical Research. Dr. Tansey, a seasoned expert in spinal cord injury medicine, will lead the development of Lifeward’s clinical research and enhance clinical partnerships. His extensive background and commitment to rehabilitation aligns with Lifeward’s mission to improve the lives of those with physical limitations. This appointment is seen as a strategic move to advance Lifeward's efforts in utilizing personal exoskeletons in therapy.
Read more →LFWDLifeward’s First Annual Step Challenge Donates €5,000 to German Association for People Living with Spinal Cord Injury
Lifeward's first ReWalk Step Challenge successfully raised €5,000 for the Association for the Promotion of Paraplegics in Germany. Over a month, ReWalk users collectively took 424,844 steps, with Lifeward contributing one cent per step. CEO Larry Jasinski expressed pride in community engagement, while FGQ Chairman Kevin Schultes emphasized the importance of received donations for their services. Lifeward plans to repeat the challenge next year, aiming for greater participation.
Read more →LFWDLifeward to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Lifeward, a leader in rehabilitation technology, announced that its CEO, Larry Jasinski, will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. This event will provide Lifeward a platform to discuss its innovative rehabilitation solutions, including the ReWalk Exoskeleton and other groundbreaking products. A recorded webcast of the presentation will be available on the company's website after the event, allowing for continued investor engagement. Lifeward aims to impact the lives of individuals with physical limitations through its advanced technology offerings.
Read more →LFWDLifeward Reports Second Quarter 2024 Financial Results
Lifeward reported a remarkable increase in revenue for Q2 2024, amounting to $6.7 million, which is over 400% higher than the same quarter last year. The company has begun receiving payments for Medicare claims from previous quarters, which has boosted their financial outlook. Lifeward also launched an innovative product line called NEO and completed an FDA submission for an advanced ReWalk design. Despite a notable increase in revenue, the company is still facing operating losses and rising expenses.
Read more →LFWDLifeward to Report Second Quarter Financial Results on August 15, 2024
Lifeward, also known as ReWalk Robotics Ltd., will announce its second quarter financial results on August 15, 2024. The announcement will be preceded by a conference call hosted by CEO Larry Jasinski and CFO Michael Lawless at 8:30 a.m. EDT. The company emphasizes its commitment to developing innovative solutions for rehabilitation and recovery, aiming to empower individuals with physical limitations.
Read more →LFWDLifeward Announces Appointment of Joseph E. Turk as Incoming Chairman of its Board of Directors
Lifeward (Nasdaq: LFWD) has announced the appointment of Joseph E. Turk as the new Chairman of its Board of Directors, following Jeff Dykan's retirement from his role. Under Dykan's leadership, Lifeward has achieved significant milestones, including regulatory approvals and acquisitions that expanded its product portfolio. Turk, who has been on the board since 2022, expressed gratitude for Dykan's contributions and emphasized a focus on commercial expansion across the company's product lines. The transition is part of Lifeward's ongoing commitment to innovation in rehabilitation technologies.
Read more →LFWDLifeward Unveils Newest Addition to Its AlterG Anti-Gravity Product Line – Introducing AlterG NEO
Lifeward has launched the AlterG NEO Anti-Gravity Treadmill, revitalizing its product line with advanced technology and an updated design. The device aims to make Anti-Gravity rehabilitation more accessible to a wider range of physical rehabilitation clinics and athletic training facilities. It features Lifeward's patented Differential Air Pressure technology, which has been a trusted element in rehabilitation for nearly two decades. The product will be showcased at the National Athletic Trainers Association Clinical Symposia & AT Expo in New Orleans on June 26 and 27, 2024.
Read more →LFWDLifeward to Present at Sidoti Virtual Investor Conference on June 12
Lifeward, a leader in rehabilitation solutions, announced its participation in the Sidoti Small Cap Conference on June 12-13, 2024, with CEO Larry Jasinski and CFO Mike Lawless presenting. The presentation will highlight the company's innovative products aimed at enhancing the lives of individuals with physical limitations. Investors can register for both the main presentation and private one-on-one meetings, which are free to attend. Lifeward emphasizes its commitment to innovation and improving health outcomes in rehabilitation and recovery.
Read more →LFWDLifeward Reports First Quarter 2024 Financial Results
Lifeward, operating under the ticker LFWD, has reported strong financial growth in Q1 2024 with revenues reaching $5.3 million, a remarkable 340% increase compared to the same period last year. The newly established Medicare payments for the ReWalk personal exoskeletons have positively impacted their financial results, as claims start getting approved. However, the company also faced operating losses of $6.5 million and a significant decline in gross margin, indicating challenges amid their growth trajectory. Looking forward, management expects sequential revenue improvements as sales capacity increases post-integration.
Read more →LFWDLifeward to Report First Quarter Financial Results on May 15, 2024
Lifeward, operating under ReWalk Robotics Ltd., announced that it will release its first quarter financial results for 2024 on May 15, before the market opens. CEO Larry Jasinski and CFO Michael Lawless are set to host a conference call at 8:30 a.m. EDT to discuss these results. The company focuses on developing innovative rehabilitation solutions that enhance the lives of individuals facing physical disabilities, underscored by its commitment to innovation and groundbreaking products.
Read more →LFWDLifeward Announces the Appointment of Mike Swinford to its Board of Directors
Lifeward, officially known as ReWalk Robotics Ltd., has appointed Mike Swinford to its Board of Directors, effective April 18, 2024. Swinford, the former CEO of Numotion, brings a wealth of experience in mobility and healthcare solutions, having expanded commercial coverage significantly during his tenure. His appointment is aimed at strengthening Lifeward's commercialization efforts and enhancing access to rehabilitation technologies for individuals with disabilities. Lifeward plans to leverage Swinford's knowledge to further its mission of delivering innovative rehabilitation solutions.
Read more →LFWDLifeward CEO Issues Open Letter to Shareholders on Progress to Finalize Exoskeleton Medicare Payment Rate
Lifeward CEO Larry Jasinski has issued a letter to shareholders detailing progress in finalizing a Medicare payment rate for ReWalk Personal Exoskeletons. The Centers for Medicare & Medicaid Services (CMS) deferred the payment rate in their recent fee schedule but confirmed it can be amended to include exoskeletons once established. Lifeward is committed to working closely with CMS to expedite this process, having already submitted several Medicare claims for reimbursement.
Read more →LFWDLifeward announces the Centers for Medicare & Medicaid Services (“CMS”) is deferring its final decision on the payment rate for personal exoskeletons so that more recent claims information on the current, more advanced ReWalk Personal Exoskeleton may be considered
Lifeward announced that the Centers for Medicare & Medicaid Services (CMS) has deferred its decision on the payment rate for personal exoskeletons, impacting how claims are handled. This decision, communicated via a HCPCS coding memorandum, indicates that the pricing will continue to be determined on a case-by-case basis until a final decision is made later this year. Meanwhile, Lifeward has delivered 35 exoskeletons to beneficiaries and remains focused on working with CMS to expedite the pricing process.
Read more →LFWDLifeward Reports Fourth Quarter and Full Year 2023 Financial Results
Lifeward, formerly known as ReWalk Robotics Ltd., reported a record annual revenue of $13.9 million for 2023, reflecting a significant increase of 151% from the previous year. The company completed its integration of former ReWalk and AlterG businesses, which is projected to generate $3 million in annual net savings. Notably, the Centers for Medicare & Medicaid Services has included exoskeletons in its 2024 Home Health Rule, enhancing potential access to Lifeward's products. Despite these positive developments, the company faces challenges with increased operating losses and declining gross margins.
Read more →LFWDLifeward to Report Fourth Quarter and Fiscal Year-End 2023 Financial Results on February 27, 2024
Lifeward, a global leader in rehabilitation solutions, announced the release date for its fourth quarter and fiscal year-end 2023 financial results. The company will disclose these results before the markets open on February 27, 2024. Following the announcement, the CEO and CFO will host a conference call to discuss the financial outcomes. Lifeward is known for its innovative products aimed at transforming rehabilitation for individuals with physical limitations.
Read more →LFWDRobotics Reports Fourth Quarter and Year End 2019 Financial Results
Robotics Reports Fourth Quarter and Year End 2019 Financial Results 2019 Total Revenue of $4.9 million and $1.2 million During the Fourth Quarter of 2019 - Completed and Pending German Insurance Contracts Establish the Implementation Procedures for Coverage of the German Spinal
Read more →LFWDRobotics Announces Pricing of $7.0 Million Public Offering
Robotics Announces Pricing of $7.0 Million Public Offering ILIT, ISRAEL / MARLBOROUGH, MA, February 6, 2020 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company") today announced the pricing of a public offering of 5,600,000 units at a price to the public of $1.25 p
Read more →LFWDReports Third Quarter 2019 Financial Results
Reports Third Quarter 2019 Financial Results - 2019 Third Quarter Total Revenues - German Tender for Exoskeletons with Major Payors Initiated - YOKNEAM ILIT, Israel / MARLBOROUGH, Mass. / BERLIN, Germany, Nov. 13, 2019 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK)
Read more →LFWDReWalk Robotics Reports Second Quarter 2019 Financial
ReWalk Robotics Reports Second Quarter 2019 Financial - 2019 second quarter total revenue of $0.9 million - & CE clearance for ReStore Exo-Suit - YOKNEAM ILIT, Israel / MARLBOROUGH, Mass., Aug. 08, 2019 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or the
Read more →LFWDReWalk Robotics Announces Pricing of
ReWalk Robotics Announces Pricing of Registered Direct Offering for $5 Million YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MASS., June 10, 2019 (GLOBE NEWSWIRE) - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company") today announced that it has entered into definitive agree
Read more →LFWDReWalk Robotics Appoints Chunlin (Allen) Han to its Board of Directors MARLBOROUGH, Mass. and
ReWalk Robotics Appoints Chunlin (Allen) Han to its Board of Directors MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, May 20, 2019 - ReWalk Robotics Ltd. (Nasdaq:RWLK) ("ReWalk" or "the Company") announced today that the Company has appointed Mr. Chunlin (Allen) Han to the board
Read more →LFWDReWalk Robotics Reports First Quarter
ReWalk Robotics Reports First Quarter 2019 Financial Results - 2019 first quarter total revenue of $1.6 million - ReStore Exo-Suit launch timeline - YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, May 7, 2019 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company") today a
Read more →LFWDReWalk Robotics Announces Pricing of Registered Direct Offering for $4,250,000 YOKNEAM ILIT, Israel and
Robotics Announces Pricing of Registered Direct Offering for $4,250,000 ILIT, Israel and MARLBOROUGH, Mass April 3, 2019 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company") today announced that it has entered into definitive agreements with institutional investors
Read more →LFWDReWalk Robotics Completes One-for-Twenty-Five Reverse
ReWalk Robotics Completes One-for-Twenty-Five Reverse YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company") reported today that it has completed the reverse share split of ReWalk ordinary
Read more →LFWDReWalk Robotics Announces Proposed Public
ReWalk Robotics Announces Proposed Public Offering of Ordinary Shares YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, February 20, 2019 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company") today announced that it intends to offer and sell, subject to market and other con
Read more →LFWDReWalk Robotics Reports Fourth Quarter
ReWalk Robotics Reports Fourth Quarter 2018 Financial Results - 2018 total revenue of $6.5 million and $1.6 million during the fourth quarter of 2018 - - Preparing for 2019 commercial launch of ReStore for stroke patients - YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, February 8,
Read more →LFWDAnnounces Preliminary Fiscal Year 2018 Revenue
Announces Preliminary Fiscal Year 2018 Revenue ReStore clinical study accrual and follow up completed - ILIT, ISRAEL / MARLBOROUGH, MA, January 14, 2019 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company") today announced preliminary, unaudited revenue for the fis
Read more →LFWDHuman and Robotic Intersection Take the Next Step 1 November 2018 ReWalk Confidential.
Human and Robotic Intersection Take the Next Step 1 November 2018 ReWalk Confidential. 2018 ReWalk Robotics, Inc. Disclaimer This presentation contains statistical data that were obtained from industry publications and reports generated by third parties. Although ReWalk believes
Read more →LFWDReWalk Robotics Reports Third Quarter
ReWalk Robotics Reports Third Quarter 2018 Financial Results - Total revenue of $1.6 million during the third quarter of 2018 - - Recruitment completed for the ReStore soft exo-suit clinical study - YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, November 8, 2018 - ReWalk Robotics L
Read more →LFWDReWalk Robotics Reports Second Quarter
ReWalk Robotics Reports Second Quarter 2018 Financial Results - Total revenue of $1.8 million during the second quarter of 2018 - - VA updates national coverage policy which expands access to ReWalk exoskeletons - YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, August 14, 2018 - ReW
Read more →LFWDReWalk Robotics Receives First Tranche of $5 Million as Part of $20 Million Strategic Investment from Timwell Corporation Limited -- ReWalk to commence strategic partnership with Timwell to commerci
ReWalk Robotics Receives First Tranche of $5 Million as Part of $20 Million Strategic Investment from Timwell Corporation Limited -- ReWalk to commence strategic partnership with Timwell to commercialize ReWalk products in China -- -- Ning Cong appointed to Board of -- Estab
Read more →LFWDReWalk Robotics Appoints Yohanan Engelhardt to its Board of Directors and as Chairman of the Audit Committee Marlborough, MA/Yokneam Ilit, Israel
Robotics Appoints Yohanan Engelhardt to its Board of Directors and as Chairman of the Audit Committee Marlborough, MA/Yokneam Ilit, Israel - May 3, 2018 -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or "the Company") announced today that the Company has appointed Yohanan E
Read more →LFWDReWalk Robotics Ltd. Appoints Ori Gon as Chief Financial Officer MARLBOROUGH, MA /
ReWalk Robotics Ltd. Appoints Ori Gon as Chief Financial Officer MARLBOROUGH, MA / YOKNEAM ILIT, ISRAEL-January 5, 2018 - ReWalk Robotics Ltd. ("ReWalk" or the "Company") (Nasdaq: RWLK) today announced the Company has appointed its Corporate Controller, Ori Gon as Chief Finan
Read more →LFWDReWalk Robotics Reports Third Quarter 2017 Financial Results -- 24% YOY growth in Q3 revenue to $1.7 million - -- Coverage allowed by DGUV and Barmer in Germany of ReWalk personal devices -- YOKNEAM
Robotics Reports Third Quarter 2017 Financial Results -- 24% YOY growth in Q3 revenue to $1.7 million - -- Coverage allowed by DGUV and Barmer in Germany of ReWalk personal devices -- YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, November 2, 2017 - ReWalk Robotics Ltd. (Nasdaq: RW
Read more →LFWDReWalk Robotics Reports Second Quarter 2017 Financial Results -- 146% YOY growth in Q2 revenue to $2 million and record 1H revenue of $4.5 million - -- 11 favorable commercial case-by-case insurance
Robotics Reports Second Quarter 2017 Financial Results -- 146% YOY growth in Q2 revenue to $2 million and record 1H revenue of $4.5 million - -- 11 favorable commercial case-by-case insurance coverage decisions -- -- 217 pending insurance claims in the U.S. and Germany -- U
Read more →LFWDReWalk Robotics Reports First Quarter 2017 Financial Results -- Record revenue of $2.5 million, up 21% over prior year quarter -- -- 14 favorable commercial case by case insurance coverage decisions
ReWalk Robotics Reports First Quarter 2017 Financial Results -- Record revenue of $2.5 million, up 21% over prior year quarter -- -- 14 favorable commercial case by case insurance coverage decisions in the US & Germany -- -- 28 units ordered for the U.S. Department of Vete
Read more →LFWDReWalk Robotics Reports Fourth Quarter and Year-End 2016 Financial Results - 2016 Full year revenue grows 57% to $5.9 million - - Year-over-year unit placements up 63%; favorable insurance reimburse
ReWalk Robotics Reports Fourth Quarter and Year-End 2016 Financial Results - 2016 Full year revenue grows 57% to $5.9 million - - Year-over-year unit placements up 63%; favorable insurance reimbursement decisions up 122% - YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, February 17,
Read more →LFWDReWalk Robotics Reports Third Quarter 2016 Financial Results -- Revenue of $1.4 million -- -- Placed 23 Personal units with 13 positive insurance decisions -- YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA
ReWalk Robotics Reports Third Quarter 2016 Financial Results -- Revenue of $1.4 million -- -- Placed 23 Personal units with 13 positive insurance decisions -- YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, November 3, 2016 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or "the Co
Read more →LFWDReWalk Robotics Announces Pricing of Public Offering of Ordinary Shares and Warrants YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA
ReWalk Robotics Announces Pricing of Public Offering of Ordinary Shares and Warrants YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, October 27, 2016 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company") today announced that it has priced its underwritten public offering
Read more →LFWDReWalk Robotics Reports Preliminary Estimated Revenues of $1.4 Million for the Third Quarter of 2016 YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA
ReWalk Robotics Reports Preliminary Estimated Revenues of $1.4 Million for the Third Quarter of 2016 YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, October 26, 2016 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company") today announced preliminary estimated revenues of a
Read more →LFWDReWalk Robotics Reports Second Quarter 2016 Financial Results --Placed 24 Personal Units, 18 of which were covered by insurance-- YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA
ReWalk Robotics Reports Second Quarter 2016 Financial Results --Placed 24 Personal Units, 18 of which were covered by insurance-- ILIT, ISRAEL / MARLBOROUGH, MA, August 4, 2016 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or "the Company") today announced its financial res
Read more →LFWDReWalk Robotics Reports First Quarter 2016 Financial Results -Growth driven by U.S. Veterans Administration and Commercial Insurance Reimbursement- YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA
Reports First Quarter 2016 Financial Results -Growth driven by U.S. Veterans Administration and Commercial Insurance Reimbursement- ILIT, ISRAEL / MARLBOROUGH, MA, May 5, 2016 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or "the Company") today announced its financial resul
Read more →LFWDReWalk Robotics Appoints Peter L. Wehrly to its Board of Directors YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA
ReWalk Robotics Appoints Peter L. Wehrly to its Board of Directors YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, April 5, 2016 - (GLOBE NEWSWIRE) - ReWalk Robotics Ltd. (Nasdaq:RWLK) ("ReWalk" or the "Company"), the leading global exoskeleton developer and manufacturer, today annou
Read more →LFWDReWalk Robotics Reports Fourth Quarter and Year-End 2015 Financial Results --Record 23 Personal Units Placed During the Fourth Quarter-- YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA
ReWalk Robotics Reports Fourth Quarter and Year-End 2015 Financial Results --Record 23 Personal Units Placed During the Fourth Quarter-- ILIT, ISRAEL / MARLBOROUGH, MA, February 25, 2016 - ReWalk Robotics Ltd. (Nasdaq:RWLK) ("ReWalk" or "the Company") today announced its fin
Read more →LFWDReWalk Robotics Reports Third Quarter 2015 Financial Results YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA
ReWalk Robotics Reports Third Quarter 2015 Financial Results YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, November 5, 2015 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or "the Company") today announced its financial results for the three- and nine-months ended September 30, 201
Read more →LFWDREWALK ROBOTICS LTD. Kochav Yokneam Building, Floor 6, Yokneam Ilit 20692, Israel Tel: (+972-4) 959-0123 Dear Shareholder, You are cordially invited to attend the 2015 annual meeting of shareholders (the " Meeting ") of
REWALK ROBOTICS LTD. Kochav Yokneam Building, Floor 6, Yokneam Tel: (+972-4) 959-0123 You are cordially invited to attend the 2015 annual meeting of shareholders (the "Meeting") of ReWalk Robotics Ltd. to be held at 16:00 p.m. (Israel time) on Thursday, December 3, 2015, at
Read more →LFWDREWALK ROBOTICS LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2015 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Consolidated Balance Sheets F-2 Consolidated Statements of Operations F-4 Statements of Ch
REWALK ROBOTICS LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS U.S. DOLLARS IN THOUSANDS Page Consolidated Balance Sheets F-2 Consolidated Statements of Operations F-4 Statements of Changes in Shareholders' Equity F-5 Consolidated Statements of Cash Flows F-6 Notes to Co
Read more →LFWDReWalk Robotics Appoints Deborah DiSanzo to its Board of Directors -Distinguished Career in Medical Device Industry; Former CEO of Philips Healthcare- YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA
Robotics Appoints Deborah DiSanzo to its Board of Directors -Distinguished Career in Medical Device Industry; Former CEO of Philips Healthcare- YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, September 16, 2015 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk"), the leading global exos
Read more →LFWDReWalk Robotics' Founder Dr. Amit Goffer to Retire Dr. Goffer leaves lasting legacy with visionary invention that enables individuals with lower limb paralysis to walk again YOKNEAM ILIT, ISRAEL / M
ReWalk Robotics' Founder Dr. Amit Dr. Goffer leaves lasting legacy with visionary invention that enables individuals with lower limb paralysis to walk again YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, August 24, 2015 - ReWalk Robotics Ltd. (Nasdaq: RWLK) today announced that its
Read more →LFWDReWalk Robotics Reports Second Quarter 2015 Financial Results YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA
ReWalk Robotics Reports Second Quarter 2015 Financial Results YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, August 6, 2015 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or "the Company") today announced its financial results for the three- and six-months ended June 30, 2015. Hig
Read more →LFWDReWalk Robotics Reports First Quarter 2015 Financial Results YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA
ReWalk Robotics Reports First Quarter 2015 Financial Results YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, May 7, 2015 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or "the Company") today announced its financial results for the three months ended March 31, 2015. Highlights of a
Read more →LFWDReWalk Robotics Reports Fourth Quarter and Year-End 2014 Financial Results Fourth Quarter Revenue Up 283% Year-Over-Year to $1.5 Million YOKNEAM ILIT, Israel and
ReWalk Robotics Reports Fourth Quarter and Year-End 2014 Financial Results Fourth Quarter Revenue Up 283% Year-Over-Year YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Feb. 12, 2015 (GLOBE NEWSWIRE) - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk," or "the Company") today announc
Read more →LFWDReWalk Robotics Appoints Kevin Hershberger as Chief Financial Officer Ami Kraft will assume new role as General Manager of ReWalk's Israel organization YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MASSACHUSE
Robotics Appoints Kevin Hershberger as Chief Financial Officer Ami Kraft will assume new role as General Manager of ReWalk's Israel organization YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MASSACHUSETTS, December 18, 2014 -- ReWalk Robotics Ltd. (Nasdaq: RWLK) announced today the app
Read more →LFWDReWalk Robotics Reports Third Quarter 2014 Financial Results Revenue up 277% year-over-year to $1.5 million Successful completion of IPO raises $38.7 million, net ReWalk becomes first and only exosk
ReWalk Robotics Reports Third Quarter 2014 Financial Results Revenue up 277% year-over-year to $1.5 Successful completion of IPO raises $38.7 ReWalk becomes first and only exoskeleton cleared by the FDA for use in the U.S. YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, November 13
Read more →LFWDREWALK ROBOTICS LTD. Kochav Yokneam Building, Floor 6, Yokneam 20692, Israel Dear Shareholder, You are cordially invited to attend an Extraordinary General Meeting of Shareholders (the " Meeting ") of ReWalk Robotics Ltd
REWALK ROBOTICS LTD. Kochav Yokneam Building, Floor 6, Yokneam You are cordially invited to attend an Extraordinary General Meeting of Shareholders (the "Meeting") of ReWalk Robotics Ltd. to be held at 4:00 p.m. (Israel time) on Monday, December 15, 2014, at the law offices o
Read more →Competitive Position
How LFWD ranks across every disease it competes inCompetitive Position is a premium feature
See how LFWD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial